Brain metastases are quite frequent in patients with ALK-translocated non-small cell lung cancer (NSCLC): they are often not amenable to surgical resection and are generally treated with radiotherapy (RT). This however causes severe late toxic side effects that may become invalidating considering the relatively long survival provided by recent medical treatment with target therapies. Several clinical trials have demonstrated that ALK-inhibitors (crizotinib, alectinib, brigatinib) show excellent activity also against brain metastases. It is therefore reasonable, in asymptomatic patients, to start treatment with specific inhibitors: RT will be used at the time of tumor progression or when symptoms appear. This sequence provides the best quality of life for patients.

ALK 易位的非小细胞肺癌 (NSCLC) 患者的脑转移非常常见：他们通常不适合手术切除，通常采用放疗 (RT) 进行治疗。然而，这会导致严重的晚期毒副作用，考虑到最近的靶向治疗药物治疗提供了相对较长的生存期，这些副作用可能会变得无效。多项临床试验表明，ALK 抑制剂（克唑替尼、艾乐替尼、布加替尼）也显示出优异的抗脑转移活性。因此，对于无症状患者，开始使用特定抑制剂治疗是合理的：在肿瘤进展时或出现症状时使用放疗。该序列为患者提供最佳生活质量。